PureTech’s Seaport Therapeutics announces an oversubscribed $225 million Series B financing round
LONDON: PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) noted that its founded entity, Seaport Therapeutics, a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the closing of an oversubscribed $225 million Series…